Literature DB >> 10618082

Recovery of Candida dubliniensis from non-human immunodeficiency virus-infected patients in Israel.

I Polacheck1, J Strahilevitz, D Sullivan, S Donnelly, I F Salkin, D C Coleman.   

Abstract

Candida dubliniensis is a recently discovered yeast species principally associated with carriage and disease in the oral cavities of human immunodeficiency virus (HIV)-infected individuals. To date the majority of isolates of this species have been identified in Europe and North America. In this study, five Candida isolates recovered from separate HIV-negative hospitalized patients in Jerusalem, Israel, were presumptively identified as C. dubliniensis on the basis of their dark green coloration when grown on CHROMagar Candida medium. Their identification was confirmed by a variety of techniques, including carbohydrate assimilation profiles, absence of growth at 45 degrees C, positive reaction with C. dubliniensis-specific antibodies as determined by indirect immunofluorescence analysis, and positive amplification with C. dubliniensis-specific PCR primers. All five strains were shown to be susceptible to a range of antifungal agents, including fluconazole. One of the five isolates was recovered from urine specimens, while the remaining four were recovered from upper respiratory tract and oral samples. While none of the patients was HIV positive, all were receiving broad-spectrum antibacterials at the time isolates of C. dubliniensis were obtained from clinical specimens. This study describes the first isolates of C. dubliniensis from the Middle East and confirms that this yeast can be associated with carriage and infection in the absence of HIV infection.

Entities:  

Mesh:

Year:  2000        PMID: 10618082      PMCID: PMC86047          DOI: 10.1128/JCM.38.1.170-174.2000

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  26 in total

1.  Correlation between in vitro susceptibility determined by E test and response to therapy with amphotericin B: results from a multicenter prospective study of candidemia.

Authors:  C J Clancy; M H Nguyen
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  Presumptive identification of an emerging yeast pathogen: Candida dubliniensis (sp. nov.) reduces 2,3,5-triphenyltetrazolium chloride.

Authors:  A Velegraki; M Logotheti
Journal:  FEMS Immunol Med Microbiol       Date:  1998-03

3.  Prevalence of Candida dubliniensis isolates in a yeast stock collection.

Authors:  F C Odds; L Van Nuffel; G Dams
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

4.  Development and characterization of complex DNA fingerprinting probes for the infectious yeast Candida dubliniensis.

Authors:  S Joly; C Pujol; M Rysz; K Vargas; D R Soll
Journal:  J Clin Microbiol       Date:  1999-04       Impact factor: 5.948

5.  A novel group I intron in Candida dubliniensis is homologous to a Candida albicans intron.

Authors:  H Boucher; S Mercure; S Montplaisir; G Lemay
Journal:  Gene       Date:  1996-11-21       Impact factor: 3.688

6.  Phylogenetic analysis and rapid identification of Candida dubliniensis based on analysis of ACT1 intron and exon sequences.

Authors:  Samantha M Donnelly; Derek J Sullivan; Diarmuid B Shanley; David C Coleman
Journal:  Microbiology       Date:  1999-08       Impact factor: 2.777

7.  Cluster of oral atypical Candida albicans isolates in a group of human immunodeficiency virus-positive drug users.

Authors:  P Boerlin; F Boerlin-Petzold; C Durussel; M Addo; J L Pagani; J P Chave; J Bille
Journal:  J Clin Microbiol       Date:  1995-05       Impact factor: 5.948

8.  Rapid identification of Candida dubliniensis by indirect immunofluorescence based on differential localization of antigens on C. dubliniensis blastospores and Candida albicans germ tubes.

Authors:  J Bikandi; R S Millán; M D Moragues; G Cebas; M Clarke; D C Coleman; D J Sullivan; G Quindós; J Pontón
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

9.  Candida dubliniensis candidemia in patients with chemotherapy-induced neutropenia and bone marrow transplantation.

Authors:  J F Meis; M Ruhnke; B E De Pauw; F C Odds; W Siegert; P E Verweij
Journal:  Emerg Infect Dis       Date:  1999 Jan-Feb       Impact factor: 6.883

10.  Candida dubliniensis sp. nov.: phenotypic and molecular characterization of a novel species associated with oral candidosis in HIV-infected individuals.

Authors:  D J Sullivan; T J Westerneng; K A Haynes; D E Bennett; D C Coleman
Journal:  Microbiology       Date:  1995-07       Impact factor: 2.777

View more
  31 in total

1.  First report of Candida dubliniensis in the Middle East.

Authors:  D A Stevens
Journal:  J Clin Microbiol       Date:  2001-01       Impact factor: 5.948

2.  One-year prevalence of Candida dublinienis in a Dutch university hospital.

Authors:  J F Meis; F M Lunel; P E Verweij; A Voss
Journal:  J Clin Microbiol       Date:  2000-08       Impact factor: 5.948

3.  Retrospective identification and characterization of Candida dubliniensis isolates among Candida albicans clinical laboratory isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected individuals.

Authors:  M A Jabra-Rizk; W A Falkler; W G Merz; A A Baqui; J I Kelley; T F Meiller
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

4.  Rapid identification and differentiation of Candida albicans and Candida dubliniensis by capillary-based amplification and fluorescent probe hybridization.

Authors:  Rangaraj Selvarangan; Ajit P Limaye; Brad T Cookson
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

5.  Identification of four distinct genotypes of Candida dubliniensis and detection of microevolution in vitro and in vivo.

Authors:  Sarah F Gee; Sophie Joly; David R Soll; Jacques F G M Meis; Paul E Verweij; Itzhack Polacheck; Derek J Sullivan; David C Coleman
Journal:  J Clin Microbiol       Date:  2002-02       Impact factor: 5.948

6.  Novel 5-flucytosine-resistant clade of Candida dubliniensis from Saudi Arabia and Egypt identified by Cd25 fingerprinting.

Authors:  Asmaa Al Mosaid; Derek J Sullivan; Itzhack Polacheck; Faisal A Shaheen; Osama Soliman; Saleh Al Hedaithy; Sahar Al Thawad; Motaz Kabadaya; David C Coleman
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

7.  Serological differentiation of experimentally induced Candida dubliniensis and Candida albicans infections.

Authors:  M D Moragues; M J Omaetxebarria; N Elguezabal; J Bikandi; G Quindós; D C Coleman; J Pontón
Journal:  J Clin Microbiol       Date:  2001-08       Impact factor: 5.948

8.  Candida dubliniensis at a university hospital in Saudi Arabia.

Authors:  R Fotedar; S S A Al-Hedaithy
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

9.  Replacement of Candida albicans with C. dubliniensis in human immunodeficiency virus-infected patients with oropharyngeal candidiasis treated with fluconazole.

Authors:  Marcos Martinez; José L López-Ribot; William R Kirkpatrick; Brent J Coco; Stefano P Bachmann; Thomas F Patterson
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

10.  Performance of selective and differential media in the primary isolation of yeasts from different biological samples.

Authors:  Jaqueline Otero Silva; Silvio Antônio Franceschini; Marco Aurélio Sicchiroli Lavrador; Regina Célia Candido
Journal:  Mycopathologia       Date:  2004-01       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.